Clinical Trial Update: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Sandostatin LAR and Axitinib vs placebo in advanced well-differentiated non-pancreatic neuroendocrine carcinomas, spanning Phase 2 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Axitinib (Axitinib)
• Sandostatin LAR (octreotide)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors, Advanced Cancer | Phase 2, Phase 3 | Status: UNKNOWN